Enveric Biosciences (ENVB) Intangibles (2015 - 2024)
Enveric Biosciences (ENVB) posted Intangibles of $42182.0 for Q4 2024, down 50.0% sequentially from $84368.0 in Q3 2024, and down 80.0% YoY from $210932.0 in Q1 2024.
Enveric Biosciences (ENVB) Intangibles (2015 - 2024) Analysis & Trends
Enveric Biosciences has reported Intangibles for 10 years, with the latest figure at $42182.0 in Q4 2024.
- Quarterly Intangibles fell 80.0% year-over-year to $42182.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $42182.0 (down 80.0% YoY) and the FY2024 annual result came in at $42182.0, down 80.0% from the prior year.
- Intangibles declined to $42182.0 in Q4 2024 per ENVB's latest filing, from $84368.0 in the prior quarter.
- Over five years, Intangibles peaked at $38.9 million in Q3 2021 and troughed at $42182.0 in Q4 2024.
- A 5-year average of $4.0 million and a median of $1.9 million in 2020 frame the typical range for Intangibles.
- The sharpest annual moves came in 2021 and 2023: Intangibles soared 1892.36% in 2021, then plunged 95.71% in 2023.
- Over 5 years, Intangibles stood at $1.8 million in 2020, then surged by 250.74% to $6.4 million in 2021, then tumbled by 94.04% to $379686.0 in 2022, then slumped by 44.45% to $210932.0 in 2023, then slumped by 80.0% to $42182.0 in 2024.
- According to Business Quant data, Intangibles over the past three periods registered $42182.0, $84368.0, and $126556.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 42,182.00 |
| Sep 30, 2024 | 84,368.00 |
| Jun 30, 2024 | 126,556.00 |
| Mar 31, 2024 | 168,744.00 |
| Dec 31, 2023 | 210,932.00 |
| Sep 30, 2023 | 253,120.00 |
| Jun 30, 2023 | 295,311.00 |
| Mar 31, 2023 | 337,498.00 |
| Dec 31, 2022 | 379,686.00 |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 6.27 Mn |
| Mar 31, 2022 | 6.97 Mn |
| Dec 31, 2021 | 6.38 Mn |
| Sep 30, 2021 | 38.87 Mn |
| Jun 30, 2021 | 2.19 Mn |
| Mar 31, 2021 | 2.36 Mn |
| Dec 31, 2020 | 1.82 Mn |
| Sep 30, 2020 | 1.95 Mn |
| Jun 30, 2020 | 2.49 Mn |
| Mar 31, 2020 | 3.04 Mn |